Cargando…

Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling

Prostate cancer (PC) is the most frequently diagnosed malignancy and a leading cause of cancer deaths in US men. Many PC cases metastasize and develop resistance to systemic hormonal therapy, a stage known as castration-resistant prostate cancer (CRPC). Therefore, there is an urgent need to develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Weijie, Lee, Adam M., Jena, Sampreeti, Huang, Yingbo, Ho, Yeung, Tietz, Kiel T., Miller, Conor R., Su, Mei-Chi, Mentzer, Joshua, Ling, Alexander L., Li, Yingming, Dehm, Scott M., Huang, R. Stephanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2023
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151558/ https://www.ncbi.nlm.nih.gov/pubmed/37068243 http://dx.doi.org/10.1073/pnas.2218522120

Ejemplares similares

A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer
por: Shan, Yuting, et al.
Publicado: (2021)

OR26-1 Alternative Polyadenylation as a Therapeutic Vulnerability in Prostate Cancer
por: Dehm, Scott, et al.
Publicado: (2022)

Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles
por: Zhang, Weijie, et al.
Publicado: (2023)

RF27 | LBSUN342 Ar-targeted Linked-read Sequencing Reveals Complex Ar Structural Variants In Castration Resistant Prostate Cancer Models
por: Zivanovic, Andrej, et al.
Publicado: (2022)

Simplicity: web-based visualization and analysis of high-throughput cancer cell line screens
por: Ling, Alexander L., et al.
Publicado: (2023)

Revealing Pan-Histology Immunomodulatory Targets in Pediatric Central Nervous System Tumors
por: Galvin, Robert T., et al.
Publicado: (2023)

Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
por: Kim, In-Wha, et al.
Publicado: (2019)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
por: Dragomir, Alice, et al.
Publicado: (2014)

Ailanthone: a new potential drug for castration-resistant prostate cancer
por: Peng, Shihong, et al.
Publicado: (2017)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes
por: Huang, Yingbo, et al.
Publicado: (2023)

Metabolomics and Biomarkers for Drug Discovery
por: Yeung, Pollen K.
Publicado: (2018)

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
por: Attard, G, et al.
Publicado: (2006)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
por: Yehya, Amani, et al.
Publicado: (2022)

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer
por: Wan, Lilin, et al.
Publicado: (2023)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer
por: Malik, Jonaid Ahmad, et al.
Publicado: (2022)

Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment
por: Fiandalo, Michael V., et al.
Publicado: (2014)

A two‐drug combination simulation study for metastatic castrate resistant prostate cancer
por: Root, Alex, et al.
Publicado: (2018)

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer
por: Fallara, Giuseppe, et al.
Publicado: (2021)

Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs
por: Ferretti, Simone, et al.
Publicado: (2023)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

Recent Advances in Prostate Cancer Treatment and Drug Discovery
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2018)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
por: Zadra, Giorgia, et al.
Publicado: (2019)

A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications
por: Shan, Yuting, et al.
Publicado: (2023)

Drug discovery of sclerostin inhibitors
por: Yu, Sifan, et al.
Publicado: (2022)

Androgen receptor: structure, role in prostate cancer and drug discovery
por: Tan, MH Eileen, et al.
Publicado: (2015)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
por: Crowley, Fionnuala, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Molecular and cellular mechanisms of castration resistant prostate cancer
por: Huang, Yiqiao, et al.
Publicado: (2018)

Antimalarial drug discovery: targeting the hypnozoite for new radical curative agent
por: Yeung, Bryan
Publicado: (2012)

Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling
por: Gruener, Robert F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jepj4qs60l2jqniufa4uj58a9l